Le Lézard
Classified in: Health
Subjects: SVY, TRI

Largest Study of Psychedelic Medicine, with 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-Home Ketamine Therapy


At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data

AUSTIN, Texas, June 14, 2024 /PRNewswire/ -- Mindbloom, the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom.

Key Findings:

"Millions of Americans are suffering from mental illness, and haven't been helped by traditional treatments," said co-author and Mindbloom Medical Director Dr. Leonardo Vando. "This study confirms that at-home ketamine therapy can be an effective and fast-acting treatment for depression and anxiety, and shows why psychedelic therapy is going to be a first-line treatment in the next few years."

The authors noted that the extensive support offered through Mindbloom ? including 1:1 coaching, therapeutic content, and group integration ? drives the effectiveness and safety of the treatment. In addition, Mindbloom's at-home ketamine therapy programs overcome barriers like cost, provider availability, and stigma that prevent people from accessing effective mental health care.

"Mindbloom's programs are successful because of our at-home model, not in spite of it," said Mindbloom's Founder and CEO Dylan Beynon. "Telehealth makes treatment more accessible and affordable, allowing clients to heal from the comfort of home. Since our launch in 2019, people have questioned whether ketamine therapy could be delivered safely and effectively at home through telehealth ? this study answers that question with an emphatic 'yes.'"

This is the second peer-reviewed study of Mindbloom's clinical outcomes. This study corroborates the findings of Mindbloom's first study over a 10X larger sample, and provides new analysis demonstrating the benefits of continuing ketamine therapy beyond the initial course of treatment.

The study also used artificial intelligence (AI) and machine learning tools to identify factors that predict whether a client will respond to treatment, providing clinicians with additional information to support their clients.

About Mindbloom:
Mindbloom is the largest provider of psychedelic medicine, with psychiatric clinicians facilitating more than 275,000 at-home ketamine therapy sessions per year in 36 states. Mindbloom offers ketamine therapy for a range of mental health issues, with programs that combine evidence-based medicine with coaching, content, and community. For more information, visit www.mindbloom.com.

Media Contact
Anna Gotskind
773-633-6606
[email protected] 

SOURCE Mindbloom


These press releases may also interest you

at 04:35
Gilead Sciences, Inc. today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial. Detailed data from the trial's interim analysis announced in June showed that lenacapavir, the company's twice-yearly injectable HIV-1...

at 03:09
Ricovr Healthcare is proud to announce that it has been awarded a competitive Small Business Innovation Research grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) for the development of its...

at 03:05
Saphetor SA, the creators of the global human genetics community VarSome, today announced European CE mark approval of the VarSome Clinical platform for the automated variant discovery, annotation, and interpretation of Next Generation Sequencing...

at 03:05
PK MED, a French biotech company, privately owned, and established in 2019 by Truffle Capital, announced it has secured a non-dilutive DeepTech financing of ? 1.5 million from Bpifrance. The funding will accelerate the company's project PKM-02, an...

at 03:00
Viewpoint, the acclaimed educational program hosted by Dennis Quaid, is excited to announce the development of a new episode in collaboration with Positive Approach to Care. This upcoming segment will focus on innovative approaches to cognitive...

at 03:00
CS Analytical Laboratory, the world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device...



News published on and distributed by: